Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance

Salarius Pharmaceuticals (SLRX), a micro-cap biotech, has secured shareholder approval for a reverse stock split (1-for-4 to 1-for-40) and the issuance of over 20% of outstanding shares to C/M Capital Master Fund, LP. These strategic moves are critical as the company faces potential Nasdaq delisting due to minimum bid price non-compliance, with an appeal planned citing its ongoing merger with Decoy Therapeutics. The recently amended merger agreement with Decoy significantly reallocates ownership, with Decoy stockholders set to hold 92.4% of the combined entity, highlighting Salarius's efforts to navigate severe financial challenges and maintain its market presence.

Analysis

Salarius Pharmaceuticals (SLRX), a micro-cap biotech with a market capitalization of $1.66 million, is undertaking critical corporate actions to address severe financial distress and a pending Nasdaq delisting notice. Shareholders have approved a reverse stock split at a ratio between 1-for-4 and 1-for-40, a measure aimed squarely at regaining compliance with Nasdaq's $1.00 minimum bid price requirement. Concurrently, the approval to issue over 20% of outstanding shares to C/M Capital Master Fund signals a necessary, but dilutive, capital infusion. The most significant development is the amended merger agreement with Decoy Therapeutics, which now allocates 92.4% of the combined entity to Decoy's stockholders, leaving Salarius legacy holders with just 7.6%. This highly dilutive reverse merger structure underscores Salarius's weak negotiating position and the high probability that its value is primarily as a public shell. Despite these strategic moves, the company's appeal against the Nasdaq delisting is not guaranteed to succeed, presenting a substantial overhang and a binary risk for the equity.

Key Decisions for Investors

• Existing shareholders must recognize the extreme dilution risk from both the impending merger with Decoy, which cedes 92.4% of the combined company, and the approved capital raise, which significantly diminishes their stake.
• The stock should be viewed as a highly speculative instrument, with its value contingent on corporate actions rather than fundamentals; any new position would be a gamble on the successful navigation of the delisting process and merger execution.
• Investors should closely monitor the outcome of the Nasdaq delisting appeal and the final closing of the Decoy merger, as these two events will be the primary determinants of any residual equity value.